![](/img/cover-not-exists.png)
1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours
G. Citterio, F.G. De Braud, V. Gregorc, T.M. De Pas, C. Noberasco, S. Boselli, M. Giovannini, F. Caligaris Cappio, A. Lambiase, C. BordignonVolume:
7
Year:
2009
Language:
english
DOI:
10.1016/s1359-6349(09)70440-9
File:
PDF, 51 KB
english, 2009